The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries.
Antidepressant treatment
Antidepressants
Major depressive disorder
Selective-serotonin reuptake inhibitors
Journal
European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Titre abrégé: Eur Arch Psychiatry Clin Neurosci
Pays: Germany
ID NLM: 9103030
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
01
08
2021
accepted:
29
11
2021
pubmed:
7
1
2022
medline:
17
5
2022
entrez:
6
1
2022
Statut:
ppublish
Résumé
Due to favorable antidepressant (AD) efficacy and tolerability, selective-serotonin reuptake inhibitors (SSRIs) are consistently recommended as substances of first choice for the treatment of major depressive disorder (MDD) in international guidelines. However, little is known about the real-world clinical correlates of patients primarily prescribed SSRIs in contrast to those receiving alternative first-line ADs. These secondary analyses are based on a naturalistic, multinational cross-sectional study conducted by the European Group for the Study of Resistant Depression at ten research sites. We compared the socio-demographic and clinical characteristics of 1410 patients with primary MDD, who were either prescribed SSRIs or alternative substances as first-line AD treatment, using chi-squared tests, analyses of covariance, and logistic regression analyses. SSRIs were prescribed in 52.1% of MDD patients who showed lower odds for unemployment, current severity of depressive symptoms, melancholic features, suicidality, as well as current inpatient treatment compared to patients receiving alternative first-line ADs. Furthermore, patients prescribed SSRIs less likely received add-on therapies including AD combination and augmentation with antipsychotics, and exhibited a trend towards higher response rates. A more favorable socio-demographic and clinical profile associated with SSRIs in contrast to alternative first-line ADs may have guided European psychiatrists' treatment choice for SSRIs, rather than any relevant pharmacological differences in mechanisms of action of the investigated ADs. Our results must be cautiously interpreted in light of predictable biases resulting from the open treatment selection, the possible allocation of less severely ill patients to SSRIs as well as the cross-sectional study design that does not allow to ascertain any causal conclusions.
Identifiants
pubmed: 34989830
doi: 10.1007/s00406-021-01368-3
pii: 10.1007/s00406-021-01368-3
pmc: PMC9095529
doi:
Substances chimiques
Antidepressive Agents
0
Antipsychotic Agents
0
Serotonin Uptake Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
715-727Informations de copyright
© 2022. The Author(s).
Références
Transl Psychiatry. 2019 Apr 3;9(1):127
pubmed: 30944309
J Clin Psychiatry. 2007 Jul;68(7):1062-70
pubmed: 17685743
Int J Psychiatry Clin Pract. 2017 Mar;21(1):13-23
pubmed: 27848269
J Affect Disord. 2021 May 15;287:204-213
pubmed: 33799039
BMC Psychiatry. 2020 Jan 3;20(1):4
pubmed: 31900133
Lancet Psychiatry. 2019 Sep;6(9):745-752
pubmed: 31303567
Focus (Am Psychiatr Publ). 2018 Oct;16(4):420-429
pubmed: 32021580
World J Biol Psychiatry. 2010 Feb;11(1):36-44
pubmed: 20146649
World J Biol Psychiatry. 2021 Jul;22(6):468-482
pubmed: 33138665
JAMA. 2010 Jan 6;303(1):47-53
pubmed: 20051569
Am J Psychiatry. 2010 Jul;167(7):745-7
pubmed: 20595426
Eur Neuropsychopharmacol. 2015 Dec;25(12):2318-25
pubmed: 26527055
J Clin Psychiatry. 2000 Sep;61(9):656-63
pubmed: 11030486
JAMA Psychiatry. 2021 Mar 1;78(3):261-269
pubmed: 33237285
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Int J Neuropsychopharmacol. 2011 Nov;14(10):1417-31
pubmed: 21349226
J Affect Disord. 2020 Apr 1;266:95-99
pubmed: 32056952
J Affect Disord. 2015 Jul 15;180:179-84
pubmed: 25911132
Eur Arch Psychiatry Clin Neurosci. 2021 Apr;271(3):417-429
pubmed: 31745646
Int Clin Psychopharmacol. 2012 Jan;27(1):8-16
pubmed: 21971532
Int Clin Psychopharmacol. 2009 May;24(3):119-25
pubmed: 19367152
Ann Intern Med. 2008 Nov 18;149(10):734-50
pubmed: 19017592
Int Clin Psychopharmacol. 2007 Nov;22(6):323-9
pubmed: 17917550
Eur Arch Psychiatry Clin Neurosci. 2021 Apr;271(3):521-526
pubmed: 32715345
J Psychopharmacol. 2013 Aug;27(8):740-58
pubmed: 23832963
Psychother Psychosom. 2019;88(4):247-248
pubmed: 31234169
World Psychiatry. 2017 Oct;16(3):317-318
pubmed: 28941085
Neuropsychopharmacology. 2008 Dec;33(13):3221-5
pubmed: 18463627
Drug Discov Today. 2019 Oct;24(10):2033-2043
pubmed: 31382015
Aust N Z J Psychiatry. 2014 Jul;48(7):663-71
pubmed: 24604920
Int J Psychiatry Clin Pract. 2017 Mar;21(1):2-12
pubmed: 28097909
World J Biol Psychiatry. 2019 Jul;20(6):427-448
pubmed: 31340696
PLoS One. 2020 Apr 21;15(4):e0231700
pubmed: 32315333
Int J Methods Psychiatr Res. 2018 Mar;27(1):
pubmed: 29498147
J Psychiatr Res. 2019 Sep;116:178-184
pubmed: 30878146
N Engl J Med. 2006 Mar 23;354(12):1231-42
pubmed: 16554525
Clin Psychopharmacol Neurosci. 2021 May 31;19(2):341-354
pubmed: 33888663
Int J Neuropsychopharmacol. 2018 Jun 1;21(6):539-549
pubmed: 29860382
Psychopharmacology (Berl). 2018 May;235(5):1455-1462
pubmed: 29480436
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
J Clin Psychopharmacol. 2003 Aug;23(4):358-64
pubmed: 12920411
Eur Neuropsychopharmacol. 2012 Jul;22(7):453-68
pubmed: 22464339
Br J Psychiatry. 2010 May;196(5):354-8
pubmed: 20435959
Br J Gen Pract. 2019 Mar;69(680):114-115
pubmed: 30819733
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Eur Neuropsychopharmacol. 2016 Dec;26(12):1960-1971
pubmed: 27816317
Int J Psychiatry Clin Pract. 2017 Sep;21(3):166-176
pubmed: 28367707
Am J Psychiatry. 2021 May 1;178(5):383-399
pubmed: 33726522
Ther Adv Psychopharmacol. 2018 Jan;8(1):49-58
pubmed: 29344343
Neuropsychiatr Dis Treat. 2019 Aug 07;15:2257-2271
pubmed: 31496708
J Psychopharmacol. 2019 Apr;33(4):482-493
pubmed: 30808242
Cogn Behav Ther. 2017 Jun;46(4):265-286
pubmed: 28440699
Int J Neuropsychopharmacol. 2016 Aug 12;19(8):
pubmed: 27488347
Psychother Psychosom. 2016;85(5):270-88
pubmed: 27508501
J Affect Disord. 2018 Feb;227:406-415
pubmed: 29154157
J Psychiatr Res. 2021 May;137:29-35
pubmed: 33647726
Eur Arch Psychiatry Clin Neurosci. 2008 Aug;258 Suppl 3:3-23
pubmed: 18668279
J Psychiatr Res. 2021 Sep;141:167-175
pubmed: 34216945
J Psychopharmacol. 2020 Dec;34(12):1335-1341
pubmed: 32900262
Ann Gen Psychiatry. 2014 Mar 19;13(1):8
pubmed: 24645830
Mol Psychiatry. 2013 Jun;18(6):692-9
pubmed: 23089630
Psychiatry Res. 2018 Jul;265:100-110
pubmed: 29702301
J Affect Disord. 2005 Apr;85(3):245-58
pubmed: 15780694
J Affect Disord. 2017 Mar 01;210:72-81
pubmed: 28013125
Ann Gen Psychiatry. 2013 Aug 13;12(1):26
pubmed: 23941527
J Affect Disord. 2020 Apr 15;267:264-282
pubmed: 32217227
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Aug 30;110:110285
pubmed: 33609603
Int J Neuropsychopharmacol. 2009 Mar;12(2):181-9
pubmed: 18662490
Lancet. 2009 Feb 28;373(9665):746-58
pubmed: 19185342
Neurosci Lett. 2018 Mar 16;669:32-42
pubmed: 27793702
Neuropsychol Rev. 2018 Mar;28(1):32-72
pubmed: 29446012
Psychother Psychosom. 2019;88(6):371-372
pubmed: 31487730